-
2010
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
-
Meet us
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
Wyeth (now Pfizer)
Zealand Pharma entered into an agreement with Wyeth in April 2003. Under this agreement, Zealand Pharma granted Wyeth exclusive, worldwide rights to co-develop, manufacture and market Rotigaptide (ZP123) for any indication, and in February 2004 extended this to new collaborative activities relating to gap-junction modulators.
In 2007 Wyeth has finalized a global multi-centre Phase IIa safety and tolerability trial with rotigaptide in patients with large myocardial infarcts.
In October 2007 Wyeth advanced the first orally available gap junction modifier Danegaptide (ZP1609/GAP-134) into phase I clinical trials in the US. Danegaptide has shown pharmacological effects in animal models of both ventricular and atrial arrhythmias, and with its oral formulation, the molecule represents a novel paradigm for the potential chronic prevention of cardiac arrhythmias.
In 2009 Wyeth was taken over by Pfizer.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 1.9.2010